BioCentury | Aug 19, 2013
Emerging Company Profile

PxRadia: Ceramide selectivity

PxRadia Inc. is developing a mAb that directly targets ceramide molecules in the cell membrane, blocking their ability to induce apoptosis in tissues subjected to stressors such as radiation. But the mAb doesn't impair normal...
BioCentury | Jun 27, 2011
Company News

Humanetics other news

HHS's Biomedical Advanced Research and Development Authority (BARDA) awarded Humanetics a two-year, $3.5 million contract for preclinical testing of BIO 300 to prevent lung injury caused by radiation exposure from a nuclear detonation. The radioprotectant...
BioCentury | Jan 21, 2008
Clinical News

BIO 300: Phase I data

In an open-label, dose-escalation, U.S. Phase I (MARC006-025) trial in adult volunteers, BIO 300 was well tolerated. The trial evaluated single oral doses of 500, 1,000, 1,500 and 2,000 mg of BIO 300. Humanetics Corp....
BioCentury | Jan 7, 2008
Product Development

ARS fallout

Osiris Therapeutics Inc. hit the jackpot last Friday, winning a $224.7 million contract from the U.S. Department of Defense to develop and stockpile the company's Prochymal to treat acute radiation sickness (ARS). But competitor Cleveland...
BioCentury | Jul 30, 2007
Clinical News

BIO 300 regulatory update

FDA granted Orphan Drug designation for BIO 300, an oral radioprotectant, for the prevention of acute radiation syndrome. Humanetics Corp. , Minneapolis, Minn. Product: BIO 300 Business: Other WIR Staff Endocrine / Metabolic...
BioCentury | Jan 15, 2007
Clinical News

BIO 300: Phase I start

Next month, Humanetics will begin a Phase I trial in about 30 healthy volunteers. Humanetics Corp. , Minneapolis, Minn. Product: BIO 300 Business: Other Molecular target: NA Description: Radioprotectant Indication: Treat and prevent acute radiation syndrome...
BioCentury | Dec 12, 2005
Company News

Humanetics, Henry M. Jackson Foundation for the Advancement of Military Medicine Inc. deal

Humanetics received an exclusive license from the foundation to develop BIO300 to protect the immune system against radiation exposure. Humanetics said the oral compound increased survival in mice that were given potentially lethal doses of...
Items per page:
1 - 7 of 7